If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
121
results.
Updated on
24/12/2025 [07:41:00]
Results 100 to 121 of 121
Absstract of: CN120865149A
The invention relates to the technical field of medicines, in particular to a 4-methylquinoline derivative as an LPAR2 inhibitor and application thereof, and provides a compound as shown in a formula (I) aiming at the problem of lack of LPAR2 targeted drugs in the prior art. In particular, in a mouse model with spinal cord injury, motor function recovery is significantly improved (BMS score is increased to 4.0), the invention also provides a pharmaceutical composition containing the compound and application of the pharmaceutical composition in prevention or treatment of LPAR2-related nervous system diseases (such as spinal cord injury, Alzheimer's disease and neuropathic pain), and the technical blank of target treatment drugs is filled.
Absstract of: CN120860018A
The invention relates to the technical field of medicines, in particular to application of SKI-178 in preparation of medicines for treating or preventing neurodegenerative diseases related to abnormal sphingomyelin metabolism. The neurodegenerative disease related to abnormal metabolism of sphingomyelin is a disease related to down-regulation of expression or activity of Sgpp2; the neurodegenerative disease is accompanied by myelin sheath injury; the neurodegenerative diseases are selected from cognitive impairment related to hyperhomocysteinemia HHcy, Alzheimer's disease, Parkinson's disease, multiple sclerosis and vascular dementia; the SKI-178 plays a therapeutic role by improving metabolic disorder of sphingomyelin and/or repairing myelin sheath injury; the application is to up-regulate the expression of the homocysteinemia virulence gene Sgpp2 and/or enhance the activity of the homocysteinemia virulence gene Sgpp2. The invention finds that the SKI-178 small-molecule compound has potential application value in treatment of neurodegenerative diseases related to hyperhomocysteinemia, myelin sheath injury and Sgpp2 gene expression abnormality, and the SKI-178 small-molecule compound has potential application value in treatment of neurodegenerative diseases related to hyperhomocysteinemia, myelin sheath injury and Sgpp2 gene expression abnormality.
Absstract of: CN120860040A
The invention provides application of a salidroside derivative SHPL-49 in preparation of a medicine for preventing/treating Alzheimer's disease (AD), and belongs to the technical field of biological medicines. The invention provides an application of a salidroside derivative SHPL-49 in preparation of a medicine for preventing/treating AD (Alzheimer's disease). According to the invention, the curative effect of the SHPL-49 on AD is evaluated by adopting two modes of preventive administration and therapeutic administration. The result shows that the SHPL-49 can effectively improve the learning and memory ability of an AD model and improve the cognitive function, and meanwhile, the brain injury is repaired. The SHPL-49 provided by the invention not only can effectively achieve the drug effect of preventing and/or treating the Alzheimer's disease, but also has good drug safety, and provides a new choice for the development of drugs for clinically treating the Alzheimer's disease.
Absstract of: CN120860083A
The invention discloses a radix cynanchi bungei exosome as well as an extraction method and application thereof, and belongs to the technical field of biology. The extraction method of the radix cynanchi bungei exosome comprises the following steps: removing root hairs from fresh radix cynanchi bungei, cutting into blocks, juicing, taking filtrate, carrying out continuous centrifugation and differential centrifugation, taking supernate, continuously carrying out ultra-high-speed centrifugation on the supernate, taking precipitate, and resuspending the precipitate, so as to obtain the radix cynanchi bungei exosome extract. According to the application of the radix cynanchi bungei exosome in preparation of the medicine for preventing and treating the Alzheimer's disease, a 3 * TgAD transgenic homozygous mouse is applied, then the extracted radix cynanchi bungei exosome is injected into the AD mouse body in a tail vein injection mode, small animal behavioristics are adopted, and the application of the radix cynanchi bungei exosome in preparation of the medicine for preventing and treating the Alzheimer's disease is achieved. The cognitive behavioral change of the mouse is observed by methods such as open field opening, new object recognition, water maze and the like, and it is verified that the radix cynanchi bungei exosome improves the cognitive impairment of the AD mouse.
Absstract of: CN120882742A
The present invention provides a humanized antibody, which comprises an antigen binding domain capable of specifically binding to an A beta 42 profibril oligomer having a beta structure, the antigen binding domain comprising: (iii) a heavy chain variable region (VH) represented by SEQ ID NO.1; or (iv) a light chain variable region (VL) containing a sequence shown in SEQ ID NO.2; or a combination thereof. Also provided are the antibodies, conjugates and pharmaceutical compositions comprising the antibodies, and nucleic acid molecules encoding the antibodies or heavy or light chain polypeptides thereof, as well as the use of vectors and host cells comprising such molecules in the treatment of amyloid disease, in particular Alzheimer's disease.
Absstract of: CN120860156A
The invention provides a traditional Chinese medicine composition for resisting Alzheimer's disease as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following active ingredients in parts by weight: 6-50 parts of gastrodia elata, 6-50 parts of uncaria rhynchophylla, 9-60 parts of concha haliotidis, 6-50 parts of prepared rehmannia root, 6-50 parts of radix cyathulae, 3-30 parts of semen raphani, 3-30 parts of eucommia ulmoides, 3-30 parts of parasitic loranthus, 3-30 parts of scutellaria baicalensis, 3-30 parts of herba lycopi, 3-30 parts of vine of multiflower knotweed and 3-30 parts of cinnabar root poria. The raw materials of the medicine are common, the preparation method is simple and easy to operate, the medicine has wide application value, after oral administration of the medicine, cognitive impairment of a transgenic mouse model of the Alzheimer's disease can be obviously improved, deposition of age pigment in brain tissue is reduced, meanwhile, the number of activated microglia and astroglia in the brain tissue is reduced, and the treatment effect of the Alzheimer's disease is improved. The compound inhibits the formation of A beta in brain tissues, and has a new application of anti-Alzheimer's disease drugs.
Absstract of: CN120882407A
The present invention relates to a liposome composition for use in a method of treating Parkinson's disease. The present invention relates to a liposome composition comprising sphingomyelin and a therapeutically effective amount of monosialotetrahexosyl ganglioside (GM1) in a lipid bilayer wherein a therapeutically effective amount of the liposome composition is administered at most every 4 days in a predominant administration manner, at least three days between each administration; preferably, the medicine is administered every 6 days at most in a main administration mode, and the time interval between every two times of administration is at least 5 days; most preferably, the medicament is administered at most every 7 days in a main administration mode, and the interval between every two administration is at least 6 days.
Absstract of: CN120866360A
There is provided a recombinant adeno-associated virus (rAAV) vector comprising one or both of (a) to (c): (a) a nucleotide sequence encoding an aromatic L-amino acid decarboxylase (AADC); (b) a nucleotide sequence for encoding glucocerebrosidase (GBA1); and (c) a nucleotide sequence encoding a neurotrophic factor (NTF), such as brain dopamine neurotrophic factor (CDNF) or glial cell-derived neurotrophic factor (GDNF), for use in the treatment of neurodegenerative disorders, in particular Parkinson's disease (PD), Multi-System Atrophy (MSA), Gaucher's disease (GD) and other proteinopathies. Also provided herein are viral particles comprising the rAAV vector, pharmaceutical compositions comprising the viral particles, and uses thereof.
Absstract of: WO2025224501A1
The invention is directed to peptide fragments of FKBP52 that inhibit Tau protein aggregation and ameliorate tauopathies like Alzheimer's Disease (AD). It also involves modifications to these peptides to improve their pharmacokinetic and pharmacodynamic properties.
Absstract of: WO2025224502A1
The invention is directed to peptide fragments of FKBP52 that inhibit Tau protein aggregation and ameliorate tauopathies like Alzheimer's Disease (AD). It also involves modifications to these peptides to improve their pharmacokinetic and pharmacodynamic properties.
Absstract of: WO2025224308A1
The current invention relates to QPCTL inhibitors represented by formula (I), and corresponding compositions and uses. Preferably, the inhibitors and compositions are for use in the treatment of cancer, neurodegenerative diseases such as Alzheimer's disease, synucleinopathies, Huntington's disease, bacterial infections such as periodontitis and related disorders, and inflammatory diseases.
Absstract of: US2025332164A1
Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
Absstract of: AU2023437235A1
A 1,4-polyisoprene dispersion system, a pharmaceutical active ingredient and the use thereof. The dispersion system is stable in the gastric acid environment of mammals without precipitation of 1,4-polyisoprene clots, has no oral toxicity to mammals, and does not contain allergens. The 1,4-polyisoprene dispersion system comprises a 1,4-polyisoprene solution dispersion system and a 1,4-polyisoprene emulsion dispersion system. The 1,4-polyisoprene dispersion system can serve as a pharmaceutical active ingredient to be used for preparing drugs for treating diseases including atherosclerotic cardiovascular and cerebrovascular diseases, type II diabetes, hypercholesterolemia, hypertriglyceridemia, fatty liver, colitis, obesity, polycystic ovarian syndrome and Alzheimer's disease.
Absstract of: AU2024260221A1
Provided herein are methods of treating diseases and disorders related to TDP-43 aggregation (e.g., ALS) with an antibody that specifically binds to OxPC or a polynucleotide encoding an antibody that specifically binds to OxPC.
Absstract of: AU2024284125A1
Disclosed herein are methods for detecting the presence of at least one misfolded form of human Superoxide Dismutase 1 (SOD1) in a biological sample obtained from a human subject. In some aspects, the subject is suspected of having, or has, one or more neurodegenerative diseases, such as, for example, Amyotrophic Lateral Sclerosis, Parkinson's disease, or Alzheimer's disease.
Absstract of: WO2025223573A1
Provided in the present invention is the use of an Achyranthes bidentata polypeptide combined with a human umbilical cord mesenchymal stem cell-derived exosome in the preparation of a drug for preventing and/or treating Parkinson's disease. A Parkinson's disease (PD) model mouse is established using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and then an Achyranthes bidentata polypeptide is used in combination with a human umbilical cord mesenchymal stem cell-derived exosome to treat the mouse. It is found that the treatment can significantly relieve PD-related symptoms, for example, restoring the number of dopaminergic neurons in the substantia nigra, improving the expression of tyrosine hydroxylase in the midbrain, relieving motor and olfactory dysfunction of the PD model mouse, reducing the activation of microglia and astrocytes in the olfactory bulb and midbrain, and improving the activity of neurons in the olfactory bulb.
Absstract of: US2025334594A1
Provided herein are methods and kits for treating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimer's Disease Parkinson's Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Kennedy's Disease, and Spinocerebellar Ataxia. Also provided are methods of predicting or measuring a response to a treatment by measuring biomarker levels in a sample, and methods of modulating biomarker levels.
Absstract of: WO2024155781A1
A method of treating and preventing Alzheimer's disease and related dementias is disclosed. The method includes administering to a patient an effective amount of a drug that is operable to inhibit an interaction between 14-3-3G protein and hexokinase-1 protein in the patient. The drug may be ezetimibe, conivaptan, lumacaftor, ebastine, digitoxin, or astemizole.
Absstract of: CN120842092A
The invention discloses a low-water-solubility medicine crystal as well as a preparation method and application thereof. The compound Z pamoate crystal form I has large characteristic diffraction peaks at one or more positions with diffraction angles 2 theta of 9.9 +/-0.2 degrees, 10.7 +/-0.2 degrees, 12.1 +/-0.2 degrees, 14.9 +/-0.2 degrees, 17.3 +/-0.2 degrees, 19.4 +/-0.2 degrees, 20.7 +/-0.2 degrees and 23.1 +/-0.2 degrees. Compared with an amorphous compound Z pamoate, the crystal provided by the invention has the advantages of good stability, no crystal transformation phenomenon, no obvious increase of related substances and low solubility; the production process is simple, only water is used as a solvent in the whole process, and no organic solvent is used; when the long-acting slow-release anti-Parkinson medicine composition is prepared from the compound Z pamoate crystal form I, the medicine encapsulation efficiency is high, the burst release is low, the composition continuously releases the medicine in vivo for more than 2 weeks, the administration frequency of a patient can be reduced, and the medication compliance is improved.
Absstract of: CN120837647A
The invention relates to the field of biological medicines, in particular to application of a reagent for inhibiting SUMOylation of a Sirt3 K288 site in preparation of a medicine for treating Parkinson's disease. The invention discloses a mechanism that MPTP induces mitochondrial complex I dysfunction and dopaminergic neuron death by destroying an AMPK-SENP1-Sirt3 pathway. The Sirt3 K288R is used for removing SUMO mutation, so that the pathological process can be effectively reversed, and the related symptoms of the Parkinson's disease can be improved. On the basis of the mechanism, a medicine taking the Sirt3 K288 site as a target spot is developed, and a brand new strategy is provided for treatment of the Parkinson's disease.
Nº publicación: CN120837498A 28/10/2025
Applicant:
BEIJING LIFE SCIENCE AND TECH RESEARCH INSTITUTE CO LTD
\u5317\u4EAC\u751F\u547D\u79D1\u6280\u7814\u7A76\u9662\u6709\u9650\u516C\u53F8
Absstract of: CN120837498A
The invention provides application of nicotine in gender-specific neuroprotective drugs, and relates to the technical field of medicines. The invention relates to application of nicotine in preparation of a sex-specific neuroprotective drug. The drug achieves the purpose of treating Parkinson's disease by improving gait parameters, improving dopaminergic neuron loss of a nigra compact part and the level of related factors, improving the level of gastrointestinal protective factors, remodeling intestinal flora and adjusting the level of metabolites. The invention systematically explains the sex difference of nicotine in preparation of neuroprotective drugs, especially in preparation of drugs for treating Parkinson's disease.
BOPI
Electronic site
